E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Thyroid eye disease (TED) |
|
E.1.1.1 | Medical condition in easily understood language |
Thyroid eye disease (TED) |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Eye Diseases [C11] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 23.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10084358 |
E.1.2 | Term | Thyroid eye disease |
E.1.2 | System Organ Class | 100000004853 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To establish the safety, tolerability, and preliminary efficacy of VRDN-001, and the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of VRDN-001 in NHV and TED patients over a dose range of 3.0 to 20.0 mg/kg. |
|
E.2.2 | Secondary objectives of the trial |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
TED subjects: 1.Be able to understand the study procedures and the risks involved and be willing to provide written informed consent before the first study-related activity 2.Be an adult male or female subject, at least 18 years of age or older 3.Have had a clinical diagnosis of Graves’ disease associated with TED with a CAS of ≥4 on the 7-item scale for the study eye 4.Have moderate to severe (an appreciable impact on daily living) active TED associated with at least one of the following: lid retraction of ≥2 mm, moderate or severe soft tissue involvement, proptosis of ≥3 mm above normal values for race and gender, and/or periodic or constant diplopia) 5.Have documented evidence of ocular symptoms or signs associated with TED that began within 1 year prior to study screening 6.Be euthyroid, or with only mild hyper- or hypothyroidism defined as free thyroxine (FT4) and free triiodothyronine (FT3) levels <50% above or below the normal limits at screening. Every effort must be made to correct any mild hypo- or hyperthyroidism promptly and maintain a euthyroid state for the entire duration of the study. Thyroidectomy is NOT an exclusion 7.Not require immediate surgical ophthalmological intervention in the study eye for any reason 8.Have alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels <3 in times the upper limit of normal (ULN) or serum creatinine <1.5 times the ULN for their age and diabetic subjects must have a glycated hemoglobin (HbA1c) of <8.5% with no new diabetic medication (oral or insulin) commenced within the previous 12 weeks, or have had more than a 10% change in the dose of a currently prescribed diabetic medication within the previous 12 weeks 9.Have a negative serum pregnancy test at screening and further negative urine tests immediately before each dose of study medication and other applicable visits following the last dose of study medication as described in Appendices 1B and 1C if the subject is a woman of childbearing potential (including those with <2 years since the onset of menopause, amenorrhea for <1 year, or not surgically sterile); such subjects must agree to use an acceptable method of contraception such as a condom and a second highly effective contraception from Screening up to and including 100 days after the last dose of study medication. If the subject is initiating hormonal contraception at time of Screening or within one cycle of Day 1, subject agrees to use a double-barrier method of contraception until completing one-full cycle of hormonal contraception. An acceptable double-barrier combination method is a condom with either diaphragm or sponge with spermicide. 10.Be surgically sterile males for at least 6 weeks, or agree to use an acceptable method of contraception such as a condom and a second highly effective contraception from Screening up to and including 100 days after the last dose of study medication 11.Be willing and able to comply with all the requirements of the protocol for the entire duration of the study
|
|
E.4 | Principal exclusion criteria |
TED Subjects: 1.Have received prior treatment with another anti-IGF-1R mAb 2.Have decreased best corrected visual acuity (BCVA) in the study eye, defined as ≥2 Snellen lines, due to optic neuropathy, new visual field defect, or color defect secondary to optic nerve involvement within previous 6 months 3.Have corneal decompensation in the study eye unresponsive to medical management 4.Have a decrease in CAS of ≥2 points between screening assessment and Day -1 5.Have a decrease in proptosis of ≥2 mm in the study eye between screening assessment and Day -1 6.Have had previous orbital irradiation or surgery in the study eye for TED 7.Have known history of clinically significant ear pathology, ear surgery or hearing impairment 8.Have inflammatory bowel disease (e.g. biopsy proven or clinical evidence of inflammatory bowel disease). 9.Have used oral corticosteroids for any condition, including TED, within 4 weeks prior to the first dose of study medication (topical is permitted) 10.Have received rituximab, or tocilizumab, or other immunosuppressive agent within 90 days prior to the first dose of study medication 11.Have received an investigational agent for any condition within 60 days 12.Have a pre-existing ophthalmic condition in the study eye, which in the opinion of the Investigator, would confound interpretation of the study results 13.Be a pregnant or lactating woman 14.Be an active alcoholic or illicit drug user or considered at high risk of relapse by the Investigator 15.Have a known hypersensitivity to any of the components of VRDN-001 or placebo formulations, or prior hypersensitivity to monoclonal antibodies (mAbs) 16.Have any condition, which in the opinion of the Investigator, would preclude inclusion in the study 17.Have a positive test to human immunodeficiency virus (HIV-1 and HIV-2) 18.Have a positive test for active hepatitis B or hepatitis C infection 19.Have previously participated in this study or any study of VRDN-001
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
SAFETY ENDPOINTS: Adverse Events (AEs), Serious Adverse Events (SAEs) and Laboratory Assessments will be monitored and recorded throughout the duration of the study. PRIMARY EFFICACY ENDPOINT: Proptosis Responder Rate (i.e., reduction of proptosis of ≥ 2 mm from baseline as measured by exophthalmometer) at 6 weeks in the MAD study, and 24 weeks in the extension cohorts |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Throughout the duration of the study At 6 and 12 weeks in the MAD study, and 24 weeks in the extension cohorts |
|
E.5.2 | Secondary end point(s) |
SECONDARY EFFICACY ENDPOINTS: Proptosis Responder Rate (i.e., reduction of proptosis of ≥ 2 mm from baseline as measured by exophthalmometer) at 12 weeks in the MAD study and at 52 weeks in the extension cohorts. Proptosis Responder Rate (i.e., reduction of proptosis of ≥ 2 mm from baseline as measured by magnetic resonance imaging [MRI]) at 6 and 12 weeks in the MAD study, and 24 and 52 weeks in the extension cohorts. Change from Baseline within the study eye (more proptotic) at 6 and 12 weeks in the MAD study, and 24 and 52 weeks in the extension cohorts in the following: • Change in measurement of proptosis by MRI • Change in measurement of proptosis by exophthalmometer • Change in volume of orbital fat as determined by MRI • Change in volume of extraocular muscles as determined by MRI • Change in facial fat volume as determined by MRI • Change in digital measurement of eye color • Change in digital and manual measurement of lid retraction • Change in clinical activity score (CAS) • Change in subjective diplopia score • Change in Graves’ Orbitopathy-Quality of Life (GO-QoL) combined score • Change in GO-QoL activity subscale • Change in GO-QoL appearance subscale • Change in Snellen best corrected visual acuity (BCVA)
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
According to the protocol |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Yes |
E.7.1.1 | First administration to humans | Yes |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 4 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 5 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 15 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Canada |
United States |
United Kingdom |
European Union |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 1 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 1 |
E.8.9.2 | In all countries concerned by the trial days | 0 |